Pharmaceutical chemistry and technology Books
Royal Society of Chemistry Basic Chemistry for Life Science Students and
Book SynopsisOrganic chemistry plays a vital role in the pharmaceutical industry. Knowledge of organic compounds is used to inform research and further the discovery and development of new medicines. Likewise, organic chemistry is fundamental to understanding biological reactions, mechanisms and all life sciences in general. Basic Chemistry for Life Science Students and Professionals is an ideal introduction to organic chemistry in the context of the life sciences and pharmacy related disciplines; utilising drug molecules to illustrate the chemical basis of their efficacy and interaction with biological targets. This book builds upon the basic concepts of organic chemistry to develop the reader’s understanding of the importance of organic chemistry to the life sciences from natural product sources, their synthesis, and approaches to drug discovery. Ideal for undergraduate students in the natural sciences, this book is also an excellent primer for postgraduates in a variety of disciplines including forensic science and allied-health programmes as well as professionals working in related fields seeking a comprehensive introduction to organic chemistry in the context of pharmaceuticals.Table of ContentsIntroduction to Organic Compounds and Covalent Bonding; Polarity of Bonds, Electronegativity, and Intermolecular Forces; Types of Organic Compounds, Nomenclature, and Basic Reactions: Alkanes and Cycloalkanes; Types of Organic Compounds, Nomenclature, and Basic Reactions: Alkenes, Cycloalkenes and Other Unsaturated Hydrocarbons; 5 Types of Organic Compounds, Nomenclature, and Basic Reactions: Functional Groups; Isomerism in Organic Compounds and Drug Molecules: Chemistry and Significance in Biology; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Amino Acids to Proteins; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Monosaccharides to Complex Carbohydrates; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Fatty Acids to Complex Lipids and Fat; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Nucleotides to Nucleic Acids; Physicochemical Properties of Organic Compounds and Drug Molecules; Drug-Target Interactions; Structural Diversity and Sources of Drugs: From Nature to Synthetic and Recombinant DNA Technology
£42.75
Taylor & Francis Inc Implementing Quality in Laboratory Policies and
Book SynopsisIn order to gain accreditation, every laboratory must have a superior quality assurance program. The keys to a successful program are the operational and technical manuals and associated documents which define the program and its various components. Written by experts with global experience in setting up laboratories, Implementing Quality in Laboratory Policies and Processes: Using Templates, Project Management, and Six Sigma provides templates for the various policies, procedures, and forms that should be contained in the quality assurance, operational, and technical manuals of a laboratory seeking accreditation.Templates for the entire project life cycleThe book begins with a general introduction and overview of quality assurance and then moves on to cover implementation strategies. It contains best practices and templates for the project management of the design and implementation of the laboratory operational and teTrade Review...The authors do deserve applause for preventing repetitions, which are the norm, rather than exceptions, in books of this kind ... it is an important book which describes how quality has to be managed in any laboratory... —Puneet Setia and Avneesh Gupta, in Anil Aggrawal's Internet Journal of Forensic Medicine and Toxicology, Volume 11, Number 2, July - December 2010Table of ContentsINTRODUCTION. POLICY TEMPLATES. Quality Assurance Program Overview. Audits, Inspections and Reviews. Document Control. Equipment and Chemicals. Personnel. Evidence. Laboratory Information Management Systems. Issue Management. Forms. CRITERIA FILES. BIBLIOGRAPHY.
£832.50
Elsevier Science Specification of Drug Substances and Products
Book Synopsis
£74.70
Elsevier Science The Organic Chemistry of Drug Design and Drug
Book SynopsisTable of Contents1. Introduction 1.1. Overview 1.2. Drugs Discovered without Rational Design 1.2.1. Medicinal Chemistry Folklore 1.2.2. Discovery of Penicillins 1.2.3. Discovery of Librium 1.2.4. Discovery of Drugs through Metabolism Studies 1.2.5. Discovery of Drugs through Clinical Observations 1.3. Overview of Modern Rational Drug Design 1.3.1. Overview of Drug Targets 1.3.2. Identification and Validation of Targets for Drug Discovery 1.3.3. Alternatives to Target-Based Drug Discovery 1.3.4. Lead Discovery 1.3.5. Lead Modification (Lead Optimization) 1.3.5.1. Potency 1.3.5.2. Selectivity 1.3.5.3. Absorption, Distribution, Metabolism, and Excretion (ADME) 1.3.5.4. Intellectual Property Position 1.3.6. Drug Development 1.3.6.1. Preclinical Development 1.3.6.2. Clinical Development (Human Clinical Trials) 1.3.6.3. Regulatory Approval to Market the Drug 1.4. Epilogue 1.5. General References 1.6. Problems References 2. Lead Discovery and Lead Modification 2.1. Lead Discovery 2.1.1. General Considerations 2.1.2. Sources of Lead Compounds 2.1.2.1. Endogenous Ligands 2.1.2.2. Other Known Ligands 2.1.2.3. Screening of Compounds 2.1.2.3.1. Sources of Compounds for Screening 2.1.2.3.1.1. Natural Products 2.1.2.3.1.2. Medicinal Chemistry Collections and Other "Handcrafted" Compounds 2.1.2.3.1.3. High-Throughput Organic Synthesis 2.1.2.3.1.3.1. Solid-Phase Library Synthesis 2.1.2.3.1.3.2. Solution-Phase Library Synthesis 2.1.2.3.1.3.3. Evolution of HTOS 2.1.2.3.2. Drug-Like, Lead-Like, and Other Desirable Properties of Compounds for Screening 2.1.2.3.3. Random Screening 2.1.2.3.4. Targeted (or Focused) Screening, Virtual Screening, and Computational Methods in Lead Discovery 2.1.2.3.4.1. Virtual Screening Database 2.1.2.3.4.2. Virtual Screening Hypothesis 2.1.2.3.5. Hit-To-Lead Process 2.1.2.3.6. Fragment-based Lead Discovery 2.2. Lead Modification 2.2.1. Identification of the Active Part: The Pharmacophore 2.2.2. Functional Group Modification 2.2.3. Structure–Activity Relationships 2.2.4. Structure Modifications to Increase Potency, Therapeutic Index, and ADME Properties 2.2.4.1. Homologation 2.2.4.2. Chain Branching 2.2.4.3. Bioisosterism 2.2.4.4. Conformational Constraints and Ring-Chain Transformations 2.2.4.5. Peptidomimetics 2.2.5. Structure Modifications to Increase Oral Bioavailability and Membrane Permeability 2.2.5.1. Electronic Effects: The Hammett Equation 2.2.5.2. Lipophilicity Effects 2.2.5.2.1. Importance of Lipophilicity 2.2.5.2.2. Measurement of Lipophilicities 2.2.5.2.3. Computer Automation of log P Determination 2.2.5.2.4. Membrane Lipophilicity 2.2.5.3. Balancing Potency of Ionizable Compounds with Lipophilicity and Oral Bioavailability 2.2.5.4. Properties that Influence Ability to Cross the Blood–Brain Barrier 2.2.5.5. Correlation of Lipophilicity with Promiscuity and Toxicity 2.2.6. Computational Methods in Lead Modification 2.2.6.1. Overview 2.2.6.2. Quantitative Structure–Activity Relationships (QSARs) 2.2.6.2.1. Historical Overview. Steric Effects: The Taft Equation and Other Equations 2.2.6.2.2. Methods Used to Correlate Physicochemical Parameters with Biological Activity 2.2.6.2.2.1. Hansch Analysis: A Linear Multiple Regression Analysis 2.2.6.2.2.2. Manual Stepwise Methods: Topliss Operational Schemes and Others 2.2.6.2.2.3. Batch Selection Methods: Batchwise Topliss Operational Scheme, Cluster Analysis, and Others 2.2.6.2.2.4. Free and Wilson or de Novo Method 2.2.6.2.2.5. Computational Methods for ADME Descriptors 2.2.6.3. Scaffold Hopping 2.2.6.4. Molecular Graphics-Based Lead Modification 2.2.7. Epilogue 2.3. General References 2.4. Problems References 3. Receptors 3.1. Introduction 3.2. Drug–Receptor Interactions 3.2.1. General Considerations 3.2.2. Important Interactions (Forces) Involved in the Drug–Receptor Complex 3.2.2.1. Covalent Bonds 3.2.2.2. Ionic (or Electrostatic) Interactions 3.2.2.3. Ion–Dipole and Dipole–Dipole Interactions 3.2.2.4. Hydrogen Bonds 3.2.2.5. Charge–Transfer Complexes 3.2.2.6. Hydrophobic Interactions 3.2.2.7. Cation–p Interaction 3.2.2.8. Halogen Bonding 3.2.2.9. van der Waals or London Dispersion Forces 3.2.2.10. Conclusion 3.2.3. Determination of Drug–Receptor Interactions 3.2.4. Theories for Drug–Receptor Interactions 3.2.4.1. Occupancy Theory 3.2.4.2. Rate Theory 3.2.4.3. Induced-Fit Theory 3.2.4.4. Macromolecular Perturbation Theory 3.2.4.5. Activation–Aggregation Theory 3.2.4.6. The Two-State (Multistate) Model of Receptor Activation 3.2.5. Topographical and Stereochemical Considerations 3.2.5.1. Spatial Arrangement of Atoms 3.2.5.2. Drug and Receptor Chirality 3.2.5.3. Diastereomers 3.2.5.4. Conformational Isomers 3.2.5.5. Atropisomers 3.2.5.6. Ring Topology 3.2.6. Case History of the Pharmacodynamically Driven Design of a Receptor Antagonist: Cimetidine 3.2.7. Case History of the Pharmacokinetically Driven Design of Suvorexant 3.3. General References 3.4. Problems References 4. Enzymes 4.1. Enzymes as Catalysts 4.1.1. What are Enzymes? 4.1.2. How do Enzymes Work? 4.1.2.1. Specificity of Enzyme-Catalyzed Reactions 4.1.2.1.1. Binding Specificity 4.1.2.1.2. Reaction Specificity 4.1.2.2. Rate Acceleration 4.2. Mechanisms of Enzyme Catalysis 4.2.1. Approximation 4.2.2. Covalent Catalysis 4.2.3. General Acid–Base Catalysis 4.2.4. Electrostatic Catalysis 4.2.5. Desolvation 4.2.6. Strain or Distortion 4.2.7. Example of the Mechanisms of Enzyme Catalysis 4.3. Coenzyme Catalysis 4.3.1. Pyridoxal 5'-Phosphate 4.3.1.1. Racemases 4.3.1.2. Decarboxylases 4.3.1.3. Aminotransferases (Formerly Transaminases) 4.3.1.4. PLP-Dependent ß-Elimination 4.3.2. Tetrahydrofolate and Pyridine Nucleotides 4.3.3. Flavin 4.3.3.1. Two-Electron (Carbanion) Mechanism 4.3.3.2. Carbanion Followed by Two One-Electron Transfers 4.3.3.3. One-Electron Mechanism 4.3.3.4. Hydride Mechanism 4.3.4. Heme 4.3.5. Adenosine Triphosphate and Coenzyme A 4.4. Enzyme Catalysis in Drug Discovery 4.4.1. Enzymatic Synthesis of Chiral Drug Intermediates 4.4.2. Enzyme Therapy 4.5. General References 4.6. Problems References 5. Enzyme Inhibition and Inactivation 5.1. Why Inhibit an Enzyme? 5.2. Reversible Enzyme Inhibitors 5.2.1. Mechanism of Reversible Inhibition 5.2.2. Selected Examples of Competitive Reversible Inhibitor Drugs 5.2.2.1. Simple Competitive Inhibition 5.2.2.1.1. Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Cancer 5.2.2.1.2. Discovery and Optimization of EGFR Inhibitors 5.2.2.2. Stabilization of an Inactive Conformation: Imatinib, an Antileukemia Drug 5.2.2.2.1. The Target: Bcr-Abl, a Constitutively Active Kinase 5.2.2.2.2. Lead Discovery and Modification 5.2.2.2.3. Binding Mode of Imatinib to Abl Kinase 5.2.2.2.4. Inhibition of Other Kinases by Imatinib 5.2.2.3. Alternative Substrate Inhibition: Sulfonamide Antibacterial Agents (Sulfa Drugs) 5.2.2.3.1. Lead Discovery 5.2.2.3.2. Lead Modification 5.2.2.3.3. Mechanism of Action 5.2.3. Transition State Analogs and Multisubstrate Analogs 5.2.3.1. Theoretical Basis 5.2.3.2. Transition State Analogs 5.2.3.2.1. Enalaprilat 5.2.3.2.2. Pentostatin 5.2.3.2.3. Forodesine and DADMe-ImmH 5.2.3.2.4. Multisubstrate Analogs 5.2.4. Slow, T ight-Binding Inhibitors 5.2.4.1. Theoretical Basis 5.2.4.2. Captopril, Enalapril, Lisinopril, and Other Antihypertensive Drugs 5.2.4.2.1. Humoral Mechanism for Hypertension 5.2.4.2.2. Lead Discovery 5.2.4.2.3. Lead Modification and Mechanism of Action 5.2.4.2.4. Dual-Acting Drugs: Dual-Acting Enzyme Inhibitors 5.2.4.3. Lovastatin (Mevinolin) and Simvastatin, Antihypercholesterolemic Drugs 5.2.4.3.1. Cholesterol and Its Effects 5.2.4.3.2. Lead Discovery 5.2.4.3.3. Mechanism of Action 5.2.4.3.4. Lead Modification 5.2.4.4. Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor and Antidiabetes Drug 5.2.5. Case History of Rational Drug Design of an Enzyme Inhibitor: Ritonavir 5.2.5.1. Lead Discovery 5.2.5.2. Lead Modification 5.3. Irreversible Enzyme Inhibitors 5.3.1. Potential of Irreversible Inhibition 5.3.2. Affinity Labeling Agents 5.3.2.1. Mechanism of Action 5.3.2.2. Selected Affinity Labeling Agents 5.3.2.2.1. Penicillins and Cephalosporins/Cephamycins 5.3.2.2.2. Aspirin 5.3.3. Mechanism-Based Enzyme Inactivators 5.3.3.1. Theoretical Aspects 5.3.3.2. Potential Advantages in Drug Design Relative to Affinity Labeling Agents 5.3.3.3. Selected Examples of Mechanism-Based Enzyme Inactivators 5.3.3.3.1. Vigabatrin, an Anticonvulsant Drug 5.3.3.3.2. Eflornithine, an Antiprotozoal Drug and Beyond 5.3.3.3.3. Tranylcypromine, an Antidepressant Drug 5.3.3.3.4. Selegiline (l-Deprenyl) and Rasagiline: Antiparkinsonian Drugs 5.3.3.3.5. 5-Fluoro-2'-deoxyuridylate, Floxuridine, and 5-Fluorouracil: Antitumor Drugs 5.4. General References 5.5. Problems References 6. DNA-Interactive Agents 6.1. Introduction 6.1.1. Basis for DNA-Interactive Drugs 6.1.2. Toxicity of DNA-Interactive Drugs 6.1.3. Combination Chemotherapy 6.1.4. Drug Interactions 6.1.5. Drug Resistance 6.2. DNA Structure and Properties 6.2.1. Basis for the Structure of DNA 6.2.2. Base Tautomerization 6.2.3. DNA Shapes 6.2.4. DNA Conformations 6.3. Classes of Drugs that Interact with DNA 6.3.1. Reversible DNA Binders 6.3.1.1. External Electrostatic Binding 6.3.1.2. Groove Binding 6.3.1.3. Intercalation and Topoisomerase-Induced DNA Damage 6.3.1.3.1. Amsacrine, an Acridine Analog 6.3.1.3.2. Dactinomycin, the Parent Actinomycin Analog 6.3.1.3.3. Doxorubicin (Adriamycin) and Daunorubicin (Daunomycin), Anthracycline Antitumor Antibiotics 6.3.1.3.4. Bis-intercalating Agents 6.3.2. DNA Alkylators 6.3.2.1. Nitrogen Mustards 6.3.2.1.1. Lead Discovery 6.3.2.1.2. Chemistry of Alkylating Agents 6.3.2.1.3. Lead Modification 6.3.2.2. Ethylenimines 6.3.2.3. Methanesulfonates 6.3.2.4. (+)-CC-1065 and Duocarmycins 6.3.2.5. Metabolically Activated Alkylating Agents 6.3.2.5.1. Nitrosoureas 6.3.2.5.2. Triazene Antitumor Drugs 6.3.2.5.3. Mitomycin C 6.3.2.5.4. Leinamycin 6.3.3. DNA Strand Breakers 6.3.3.1. Anthracycline Antitumor Antibiotics 6.3.3.2. Bleomycin 6.3.3.3. Tirapazamine 6.3.3.4. Enediyne Antitumor Antibiotics 6.3.3.4.1. Esperamicins and Calicheamicins 6.3.3.4.2. Dynemicin A 6.3.3.4.3. Neocarzinostatin (Zinostatin) 6.3.3.5. Sequence Specificity for DNA-Strand Scission 6.4. General References 6.5. Problems References 7. Drug Resistance and Drug Synergism 7.1. Drug Resistance 7.1.1. What is Drug Resistance? 7.1.2. Mechanisms of Drug Resistance 7.1.2.1. Altered Target Enzyme or Receptor 7.1.2.2. Overproduction of the Target Enzyme or Receptor 7.1.2.3. Overproduction of the Substrate or Ligand for the Target Protein 7.1.2.4. Increased Drug-Destroying Mechanisms 7.1.2.5. Decreased Prodrug-Activating Mechanism 7.1.2.6. Activation of New Pathways Circumventing the Drug Effect 7.1.2.7. Reversal of Drug Action 7.1.2.8. Altered Drug Distribution to the Site of Action 7.2. Drug Synergism (Drug Combination) 7.2.1. What is Drug Synergism? 7.2.2. Mechanisms of Drug Synergism 7.2.2.1. Inhibition of a Drug-Destroying Enzyme 7.2.2.2. Sequential Blocking 7.2.2.3. Inhibition of Targets in Different Pathways 7.2.2.4. Efflux Pump Inhibitors 7.2.2.5. Use of Multiple Drugs for the Same Target 7.3. General References 7.4. Problems References 8. Drug Metabolism 8.1. Introduction 8.2. Synthesis of Radioactive Compounds 8.3. Analytical Methods in Drug Metabolism 8.3.1. Sample Preparation 8.3.2. Separation 8.3.3. Identification 8.3.4. Quantification 8.4. Pathways for Drug Deactivation and Elimination 8.4.1. Introduction 8.4.2. Phase I Transformations 8.4.2.1. Oxidative Reactions 8.4.2.1.1. Aromatic Hydroxylation 8.4.2.1.2. Alkene Epoxidation 8.4.2.1.3. Oxidations of Carbons Adjacent to sp2 Centers 8.4.2.1.4. Oxidation at Aliphatic and Alicyclic Carbon Atoms 8.4.2.1.5. Oxidations of Carbon–Nitrogen Systems 8.4.2.1.6. Oxidations of Carbon–Oxygen Systems 8.4.2.1.7. Oxidations of Carbon–Sulfur Systems 8.4.2.1.8. Other Oxidative Reactions 8.4.2.1.9. Alcohol and Aldehyde Oxidations 8.4.2.2. Reductive Reactions 8.4.2.2.1. Carbonyl Reduction 8.4.2.2.2. Nitro Reduction 8.4.2.2.3. Azo Reduction 8.4.2.2.4. Azido Reduction 8.4.2.2.5. Tertiary Amine Oxide Reduction 8.4.2.2.6. Reductive Dehalogenation 8.4.2.3. Carboxylation Reaction 8.4.2.4. Hydrolytic Reactions 8.4.3. Phase II Transformations: Conjugation Reaction 8.4.3.1. Introduction 8.4.3.2. Glucuronic Acid Conjugation 8.4.3.3. Sulfate Conjugation 8.4.3.4. Amino Acid Conjugation 8.4.3.5. Glutathione Conjugation 8.4.3.6. Water Conjugation 8.4.3.7. Acetyl Conjugation 8.4.3.8. Fatty Acid and Cholesterol Conjugation 8.4.3.9. Methyl Conjugation 8.4.4. Toxicophores and Reactive Metabolites (RMs) 8.4.5. Hard and Soft (Antedrugs) Drugs 8.5. General References 8.6. Problems References 9. Prodrugs and Drug Delivery Systems 9.1. Enzyme Activation of Drugs 9.1.1. Utility of Prodrugs 9.1.1.1. Aqueous Solubility 9.1.1.2. Absorption and Distribution 9.1.1.3. Site Specificity 9.1.1.4. Instability 9.1.1.5. Prolonged Release 9.1.1.6. Toxicity 9.1.1.7. Poor Patient Acceptability 9.1.1.8. Formulation Problems 9.1.2. Types of Prodrugs 9.2. Mechanisms of Drug Inactivation 9.2.1. Carrier-Linked Prodrugs 9.2.1.1. Carrier Linkages for Various Functional Groups 9.2.1.1.1. Alcohols, Carboxylic Acids, and Related 9.2.1.1.2. Amines and Amidines 9.2.1.1.3. Sulfonamides 9.2.1.1.4. Carbonyl Compounds 9.2.1.2. Examples of Carrier-Linked Bipartite Prodrugs 9.2.1.2.1. Prodrugs for Increased Water Solubility 9.2.1.2.2. Prodrugs for Improved Absorption and Distribution 9.2.1.2.3. Prodrugs for Site Specificity 9.2.1.2.4. Prodrugs for Stability 9.2.1.2.5. Prodrugs for Slow and Prolonged Release 9.2.1.2.6. Prodrugs to Minimize Toxicity 9.2.1.2.7. Prodrugs to Encourage Patient Acceptance 9.2.1.2.8. Prodrugs to Eliminate Formulation Problems 9.2.1.3. Macromolecular Drug Carrier Systems 9.2.1.3.1. General Strategy 9.2.1.3.2. Synthetic Polymers 9.2.1.3.3. Poly(a-Amino Acids) 9.2.1.3.4. Other Macromolecular Supports 9.2.1.4. Tripartite Prodrugs 9.2.1.5. Mutual Prodrugs (also called Codrugs) 9.2.2. Bioprecursor Prodrugs 9.2.2.1. Origins 9.2.2.2. Proton Activation: An Abbreviated Case History of the Discovery of Omeprazole 9.2.2.3. Hydrolytic Activation 9.2.2.4. Elimination Activation 9.2.2.5. Oxidative Activation 9.2.2.5.1. N- and O-Dealkylations 9.2.2.5.2. Oxidative Deamination 9.2.2.5.3. N-Oxidation 9.2.2.5.4. S-Oxidation 9.2.2.5.5. Aromatic Hydroxylation 9.2.2.5.6. Other Oxidations 9.2.2.6. Reductive Activation 9.2.2.6.5. Nitro Reduction 9.2.2.7. Nucleotide Activation 9.2.2.8. Phosphorylation Activation 9.2.2.9. Sulfation Activation 9.2.2.10. Decarboxylation Activation 9.3. General References 9.4. Problems References Appendix Index
£75.04
Elsevier Science Surfactants in Biopharmaceutical Development
Book SynopsisTable of Contents1. Introduction 2. Polysorbate Surfactants used in biopharmaceuticals: An overview including in vivo fate and toxicology perspective 3. Surfactants (polysorbate and poloxamer) synthesis and degradation: Overview and relevance 4. Mechanisms of stabilization of proteins by surfactants 5. Behaviour of surfactant during processing (UF/DF, filter adsorption) 6. Analytical methods for surfactant characterization in Drug Product 7. Oxidative degradation of surfactants: Mechanisms 8. Hydrolytic degradation of surfactants and impact on protein stabilization 9. Regulatory Perspective on Surfactant Monitoring and Control 10. Control strategies to address surfactant degradation: A quality perspective 11. A look to the future - closing remarks
£121.50
Oxford University Press Drug Design and Development
Book SynopsisDrug Design and Development outlines the processes involved in the design and development of new drugs and emphasises the significance of these processes to the practice of pharmacy. The book highlights why it is important that all practicing pharmacists, including those working in hospitals or high street stores, have a solid understanding of the process of the design and development of the drugs they interact with. It adopts an integrated approach, formulated to complement courses which are designed in line with the General Pharmaceutical Council''s new curriculum requirements. Furthermore, this is the only integrated textbook to consider both drug design and development within one volume. Throughout the book, the journey of the drug, from discovery to market, is presented in an integrated fashion, emphasising the interconnection of all the processes involved.Trade ReviewWell written text that guides students through the complex elements of the drug development process. It has a chemistry focus and utilises 'key points' to reinforce the important aspects at regular opportunities. * Dr James F. Brown, University of Portsmouth *Table of Contents1: Introduction Part 1 Drug targets 2: Receptors and signal transduction 3: Enzymes as drug targets 4: Nucleic acids and protein synthesis as drug targets 5: Other drug targets Part 2 Origins of drug molecules 6: Sources of lead compounds 7: Drug synthesis 8: Optimisation of lead compounds 9: Computer-aided drug design 10: Combinatorial chemistry and high-throughput screening 11: Biotechnology and biopharmaceuticals Part 3 Biological aspects of drug development 12: Drug metabolism 13: Pharmacogenetics and pharmacogenomics 14: Toxicity testing Part 4 Preformulation studies 15: Solubility and drug development 16: Solid state characteristics 17: Drug stability Part 5 Clinical research 18: Clinical research and its regulation 19: Design and management of clinical trials
£37.99
Indiana University Press Death to Beauty The Transformative History of
Book SynopsisTrade Review"A riveting text that bridges biography, history, and medicine, Death to Beauty is a must-read for anyone interested in the story of how Dr. Alan Scott, working almost independently and with few resources, transformed the world's deadliest toxin into a wonder drug that has not only become a multi-billion-dollar industry, but a medical and cultural phenomenon."—Dana Berkowitz, author of Botox Nation: Changing the Face of America"Expertly written and thoroughly researched, Dr. Helveston meticulously outlines the history of Botox and the pivotal role that Dr. Alan Scott played in bringing Botox safely to millions of people across the globe."—Christie L. Morse, MD, Concord Eye Center"Dr. Helveston has painstakingly researched the life and accomplishments of Alan B. Scott MD, one of the most brilliant minds in medicine and creator of botulinum toxin (Botox) for the treatment of many conditions. This book is a page burner, interesting, and still very thorough. I highly recommend it to clinicians and non-clinicians alike."—William Good, MD, Senior Scientist at Smith-Kettlewell Eye Research Institute"At the heart of this book is the curiosity and determination of one man, Alan Scott. Helveston's compelling narrative makes botulinum toxin understandable, all the while tracing the fine line that distinguishes poison from medicine. Death to Beauty is an important addition to the history of medicine."—Edward O'Malley, MD, Senior Staff Physician Emeritus, Henry Ford Health"Eugene Helveston, M.D. documents the amazing story of Botulinum toxin from a deadly problem to a very important therapeutic advance for patients with multiple types of neurological conditions, from various movement disorders' treatment to helping alleviating the misery of migraine headaches. Botulinum toxin has been a great advance for neurologists treating many needy patients."—David A. Josephson, M.D., Josephson-Wallack-Munshower Neurology, P.C."Dr. Scott would be proud and grateful."—C. William Hanke, MD, MPH, Former President, American Academy of Dermatology
£18.04
MIT Press Ltd Quantitative Fundamentals of Molecular and
Book SynopsisA comprehensive presentation of essential topics for biological engineers, focusing on the development and application of dynamic models of biomolecular and cellular phenomena.This book describes the fundamental molecular and cellular events responsible for biological function, develops models to study biomolecular and cellular phenomena, and shows, with examples, how models are applied in the design and interpretation of experiments on biological systems. Integrating molecular cell biology with quantitative engineering analysis and design, it is the first textbook to offer a comprehensive presentation of these essential topics for chemical and biological engineering.The book systematically develops the concepts necessary to understand and study complex biological phenomena, moving from the simplest elements at the smallest scale and progressively adding complexity at the cellular organizational level, focusing on experimental testing of mechanistic hypotheses. After i
£68.40
Pearson Education (US) Medicinal Chemistry
Book SynopsisTable of Contents1 A Brief History of Drug Discovery 2 The Modern Drug Process 3 A Trip through the Body 4 Enzymes as Drug Targets 5 Receptors as Drug Targets 6 Oligonucleotides as Drug Targets 7 Pharmacokinetics 8 Metaboism 9 Molecular Structure and Diversity 10 Lead Discovery 11 Lead Optimization- Traditional Methods 12 Lead Optimization- Hansch Analysis 13 Aspects in Pharmaceutical Synthesis
£154.10
Taylor & Francis Ltd RealWorld Evidence in Drug Development and
Book SynopsisReal-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field.Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions.Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outTable of Contents1 Using Real-world Evidence to Transform Drug Development: Opportunities and Challenges. 2. Evidence derived from real world data: utility, constraints and cautions. 3. Real-World Evidence from Population-Based Cancer Registry Data. 4. External Control using RWE and Historical Data in Clinical Development. 5. Bayesian method for assessing drug safety using real-world evidence. 6. Real-World Evidence for Coverage and Payment Decisions. 7. Causal Inference for Observational Studies/Real-World Data. 8. Introduction to Artificial Intelligence and Deep Learning with a Case Study in Analyzing Electronic Health Records for Drug Development.
£114.00
CRC Press Innovative Statistics in Regulatory Science
Book SynopsisStatistical methods that are commonly used in the review and approval process of regulatory submissions are usually referred to as statistics in regulatory science or regulatory statistics. In a broader sense, statistics in regulatory science can be defined as valid statistics that are employed in the review and approval process of regulatory submissions of pharmaceutical products. In addition, statistics in regulatory science are involved with the development of regulatory policy, guidance, and regulatory critical clinical initiatives related research. This book is devoted to the discussion of statistics in regulatory science for pharmaceutical development. It covers practical issues that are commonly encountered in regulatory science of pharmaceutical research and development including topics related to research activities, review of regulatory submissions, recent critical clinical initiatives, and policy/guidance development in regulatory science. Devoted enTable of Contents1. Introduction. 2. Totality-of-the-Evidence. 3. Hypotheses Testing Versus Confidence Interval. 4. Endpoint Selection. 5. Non-inferiority Margin. 6. Missing Data. 7. Multiplicity. 8. Sample Size. 9. Reproducible Research. 10. Extrapolation. 11. Consistency Evaluation. 12. Drug Products with Multiple Components. 13. Adaptive Trial Design. 14. Selection Criteria in Adaptive Dose Finding. 15. Generic Drugs and Biosimilars. 16. Precision and Personalized Medicine. 17. Big Data Analytics. 18. Rare Disease Drug Development.
£114.00
CRC Press Handbook of Microbiological Quality Control in
Book SynopsisMicrobiologists working in both the pharmaceutical and medical device industries, face considerable challenges in keeping abreast of the myriad microbiological references available to them, and the continuously evolving regulatory requirements. The Handbook of Microbiological Quality Control provides a unique distillation of such material, by providing a wealth of microbiological information not only on the practical issues facing the company microbiologist today, but also the underlying principles of microbiological quality assurance. All the chapters have been written by leading experts in this field. The Handbook of Microbiological Quality Control provides guidance on safe microbiological practices, including laboratory design and sampling techniques. The design storage, use and quality control of microbiological culture is considered in depth. Principles of enumeration and identification of micro-organisms, using both traditional and rapid methods as well as the pharmacopoeial methTable of ContentsSafety in Microbiology. Culture Media. Sampling. Enumeration of Micro-organisms. Identification of Micro-organisms. Specified Organisms. Rapid Methods. Sterility Assurance. Endotoxin Testing. Preservative Efficacy Testing. Microbiological Assay. Disinfection and Cleansing. Microbiological Audit. Case Studies and Calculations.
£58.89
CRC Press Chromatographic Techniques in the Forensic
Book SynopsisThere is a dramatic rise of novel drug use due to the increased popularity of so-called designer drugs. These synthetic drugs can be illegal in some countries, but legal in others and novel compounds unknown to drug chemistry emerge monthly. This thoughtfully constructed edited reference presents the main chromatographic methodologies and strategies used to discover and analyze novel designer drugs contained in diverse biological materials. The methods are based on molecular characteristics of the drugs belonging to each individual class of compounds, so it will be clear how the current methods are adaptable to future new drugs that appear in the market.Table of ContentsIntroduction. Designer Drugs: Legislating for Tomorrow Through the Use of Class Definitions and Pharmacophore Principles. Alternative Legislation with Designer Drugs. Biological Precursors of Designer Drugs. Liquid Chromatography – Mass Spectrometry in Analysis of Designer Drugs. Ambient Plasma Ionization Techniques in Forensic Analysis. Application of LC-QTOFMS for the Identification of the Structure of New Psychoactive Substances. Rapid Generation of Metabolites by Electrochemical Method. Gas Chromatography – Mass Spectrometry in Analysis of Designer Drugs. NMR Spectroscopy in the Analysis of Designer Drugs. Preparation of Biological Material for Toxicological Analysis. Discrimination among the Designer Drug Isomers by Chromatographic and Spectrometric Methods. Liquid Chromatography-Mass Spectrometry and Ambient Mass Spectrometry Applied to the Analysis of Synthetic Cannabinoids. Cathinone Derivatives and Their Analysis. NBOMe Derivatives of Phenylethylamines and Their Analysis. 2C Derivatives of Phenylethylamines and Their Analysis. Modern Techniques for the Analysis of Piperazines. Fenantyl Analogues and Their Analysis. Modern Techniques for the Identification of Tryptamines. Toxicological Analysis of New Opioids. Toxicological Analysis of Designer Benzodiazepines. Thin-layer Chromatography in the Analysis of Designer Drugs
£43.69
CRC Press Handbook of Validation in Pharmaceutical
Book SynopsisRevised to reflect significant advances in pharmaceutical production and regulatory expectations, Handbook of Validation in Pharmaceutical Processes, Fourth Edition examines and blueprints every step of the validation process needed to remain compliant and competitive. This book blends the use of theoretical knowledge with recent technological advancements to achieve applied practical solutions. As the industry's leading source for validation of sterile pharmaceutical processes for more than 10 years, this greatly expanded work is a comprehensive analysis of all the fundamental elements of pharmaceutical and bio-pharmaceutical production processes. Handbook of Validation in Pharmaceutical Processes, Fourth Edition is essential for all global health care manufacturers and pharmaceutical industry professionals.Key Features: Provides an in-depth discussion of recent advances in sterilization Identifies obstacles tTable of Contents1. Why Validation?, 2. Facility Design for Validation, 3. Modular Facilities – Meeting the Need for Flexibility, 4. Commissioning and Qualification, 5. Design & Quaification of Controlled Environments, 6. Validation of Pharmaceutical Water Systems, 7. Validation of Critical Utilities, 8. Calibration and Metrology, 9. Risk Management and Thermal Validation, 10. Change Control, 11. MICROBIOLOGY OF STERILIZATION PROCESSES, 12. Biological Indicators, 13. Steam Sterilization in Autoclaves, 14. Validation of Terminal Sterilization, 15. Steam Sterilization-in-Place Technology and Validation, 16. Dry Heat Sterilization, 17. Depyrogenation by Inactivation and Removal, 18. Ethylene Oxide Sterilization, 19. Validation of chlorine dioxide Sterilization, 20. Liquid Phase Sterilization, 21. Vapor Sterilization and Decontamination, 22. Validation of the Radiation Sterilization of Pharmaceuticals, 23. Validation of Sterilizing Grade Filters, 24. Disinfecting Agents: The Art of Disinfection, 25. Cleaning and Disinfecting Laminar Flow Workstations, Bio Safety Cabinets and Fume Hoods, 26. Contamination Control for Component Introduction to Classified Areas, 27. Aseptic Processing for Dosage Form Manufacture, 28. Validation of Manual Aseptic Processes, 29. Validation of Aseptic Processing for Bulk Pharmaceutical Chemicals, 30. Qualification and Validation of Advanced Aseptic Processing Technologies, 31. Total Particle Monitoring, 32. Environmental Monitoring, 33. Validation of Container Component Preparation, 34. Validation of Lyophilization, 35. Validation of Packaging Processes for Sterile Products, 36. Validation of Active Pharmaceutical Ingredients, 37. Cell Culture Process Validation including Cell Bank Qualification, 38. Validation of Recovery and Purification Processes, 39. Validation of Process Chromatography, 40. Single Use Technologies and Systems, 41. Considerations for Process Validation for Cell and Gene Therapies, 42. Validation of Solid Dosage Forms, 43. Validation of Validation of Oral / Topical Liquids & Semi-Solids, 44. Validation of Non-Sterile Packaging Operations, 45. Validation of Cleaning Processes, 46. Validation of Training, 47. Vendor Qualification and Validation, 48. Validation of Clinical Trial Manufacturing, 49. Validation of New Products, 50. Retrospective / Continuous Process Validation, 51. Validation & 6 Sigma, 52. Validation and Contract Manufacturing, 53. Computerized Systems Validation, 54. Risk Based Validation of Laboratory Information Management Systems, 55. Control Systems Validation, 56. Process Analytical Technology and Validation, 57. Validation of Analytical Procedures and Physical Methods, 58. Validation of Microbial Methods, 59. "Rapid Methods for Aseptic Processing and Their Validation", 60. Extractables and Leachables in Drug Products: An Overview, 61. Evolution and Implementation of Validation in the United States, 62. Validation in Europe - What are the Differences?, 63. Japanese Approach to Validation, 64. Organization of Validation in a MultiNational Pharmaceutical Company, 65. Validation in a Small Pharmaceutical Company, 66. Regulatory Aspects of Process Validation in the United States, 67. The Future of Validation
£204.25
Taylor & Francis Ltd Wild Plants The Treasure of Natural Healers
Book SynopsisThis book offers a broad summary of the wild plants and their usage, as well as the growing interest in ethnopharmacology research. The book comprises of important issues such as diversity of wild plants with emphasis on medicinal and food plants, threats to wild plants and traditional ethnobotanical knowledge, their uses in skin diseases, snake-bites, in cosmeceuticals, etc. Moreover, the ethnopharmacological relevance of wild plants in Latin America has been discussed. The chapters include a wide range of case studies, giving updated evidence on the importance of their wild plant resources from different countries including Peru, Nepal, Bangladesh, India, Pakistan, Brazil. In addition, some specific species are used to explain their potential properties, as well as the dangers of their use without guidance of trained natural healers. The book discusses traditional usage and properties of wild plants and is entirely different from other related publications and useful for the reseaTable of ContentsGENERAL. Wild Plants as a Treasure of Natural Healers: The Need for Unlocking the Treasure. The Disappearance and Substitution of Native Medicinal Species. SPECIFIC COUNTRIES. Wild Plants of Northern Peru: Traditions, Scientific Knowledge and Innovation. Ethnic Uses of Plant Species among Magar People in Nepal. Some Plants Used as Phytomedicine by Tribal Healers of Chittagong Hill Tracts, Bangladesh. Argentinian Wild Plants as Controllers of Fruits Phytopathogenic Fungi: Trends and Perspectives. Plants from Brazil used against Snake Bites: Oleanolic and Ursolic Acids as Antiophidian against Bothrops jararacussu venom. Latin American Endemic (Wild) Medicinal Plants with High-Value: Ethnobotanical, Pharmacological, and Chemical Importance. Phytochemicals from Wild Medicinal and Aromatic Plants of Argentina. The Zig-Zag Trail of Symbiosis among Chepang, Bat, and Butter Tree: An Analysis on Conservation Threat in Nepal. SPECIFIC PLANTS AND AILMENTS. Role of Wild Plants in Curing and Healing the Skin Diseases. Choerospondias axillaris (Hog plum): Multiple Health Benefits. Artemisia Species: Medicinal Values with Potential Therapeutic Uses. The Potential Use of Mandacaru (Cereus spp.) Bioactive Compounds. Subfamily Bombacoideae: Traditional Uses, Secondary Metabolites, Biological Activities and Mechanistic Interpretation of the Anti-Inflammatory Activity. Ayahuasca: Inherent Dangers in Its Consumption. Exploring the Plant Kingdom for Sources of Skincare Cosmeceuticals: From Indigenous Knowledge to the Nanotechnology Era. Ethnomedicinal and Pharmacological Importance of Glycyrrhiza glabra L.
£175.75
Taylor & Francis Ltd RealWorld Evidence in a PatientCentric Digital
Book SynopsisReal-world evidence is defined as evidence generated from real-world data outside randomized controlled trials. As scientific discoveries and methodologies continue to advance, real-world data and their companion technologies offer powerful new tools for evidence generation. Real-World Evidence in a Patient-Centric Digital Era provides perspectives, examples, and insights on the innovative application of real-world evidence to meet patient needs and improve healthcare, with a focus on the pharmaceutical industry.This book presents an overview of key analytical issues and best practices. Special attention is paid to the development, methodologies, and other salient features of the statistical and data science techniques that are customarily used to generate real-world evidence. It provides a review of key topics and emerging trends in cutting-edge data science and health innovation.Features: Provides an overview Table of ContentsPreface: Real World Evidence and Digital Innovation to Combat Noncommunicable Diseases. 1. Real World Evidence Generation. 2. Applications of RWE for Regulatory Uses. 3. Ethics & Bioethics. 4. Real- World Data, Big Data and Artificial Intelligence: Recent Development and Emerging Trends in the European Union. 5. Patient centricity and Precision Medicine. 6. Health Information Technology. 7. Digital Health Technologies and Innovations. 8. Economic Analysis and Outcome Assessment. 9. Partnerships and Collaborations. 10. Global Perspective: China Big Data Collaboration to Improve Patient Care. 11. The Future of Patient-Centric Data-Driven Healthcare
£99.75
Taylor & Francis Ltd Drug Misuse and Community Pharmacy
Book SynopsisDrug misuse is a major challenge for health professionals in the 21st century, and community pharmacy holds a key place in the management of prescribed medication, the provision of health education and promotion messages to drug users. Two decades ago there would have been no need for a book to describe such the role of community pharmacy; however, since more people are injecting drugs now and HIV is on the rise, community pharmacists have found their services in higher demand. The quality practice of tomorrow hinges on trained and competent practitioners working in a variety of community pharmacy settings. Drug Misuse and Community Pharmacy explains the historical, research and practical aspects. Experts use a practical and evidence-based approach to educate students of pharmacy, pre-registration pharmacists, community pharmacists working with drug users and anyone involved in developing and managing primary healthcare for drug misusers.Table of ContentsPart 1: Background. Opiate Addiction and the British System: Looking Back on the Twentieth Century and Trying to see its Shape in the Future. Drug Misuse and the Community Pharmacist: a Historical Overview. Part 2: Surveying the Situation. Reviewing the Situation - Pharmacists and Drug Misuse Services in England and Wales. Drug Misuse and Community Pharmacy in Scotland. Drug Misuse in Northern Ireland: the Role of the Community Pharmacist. Drug Users and Pharmacists: the Client Perspective. Part 3: Working with Drug Users. The History and Operation of Pharmacy Needle Exchanges. New Approaches to Dispensing Controlled Drugs: Supervised Consumption. Providing Health Care for Drug Users. Misuse Over-the-Counter Products. Part 4: Practical Matters - Training, Support and Shared Care. Legal and Ethical Considerations for Community Pharmacists. Training and Support for Pharmacists. Professional Conflicts for the Front-Line Community Pharmacist. Shared Care at the Primary and Secondary Interface: The Role of GPs and Specialist Drug Services. Part 5: The Way Forward. The Way Forward - Greater Specialism or More Generalism?
£54.14
Taylor & Francis Ltd Enzymes and Their Inhibitors
Book SynopsisFocusing on the development of enzyme inhibitors as therapeutic drugs, Enzymes and Their Inhibitors: Drug Development provides a concise overview of the chemistry of major types of enzymes and their inhibitors. The opening chapters introduce readers to the structure, functions, mechanisms, and kinetics of enzymes, including their use as disease markers, analytical reagents, and in industrial processes. Subsequent chapters discuss the different types of enzyme inhibitors and the principles involved in developing them into effective drugs. This outstanding text, also valuable as a professional reference, will be useful to all students of pharmacology and medicinal chemistry.Table of ContentsFocusing on the development of enzyme inhibitors as therapeutic drugs, Enzymes and Their Inhibitors: Drug Development provides a concise overview of the chemistry of major types of enzymes and their inhibitors. The opening chapters introduce readers to the structure, functions, mechanisms, and kinetics of enzymes, including their use as disease markers, analytical reagents, and in industrial processes. Subsequent chapters discuss the different types of enzyme inhibitors and the principles involved in developing them into effective drugs. This outstanding text, also valuable as a professional reference, will be useful to all students of pharmacology and medicinal chemistry.
£218.50
Elsevier Science Progress in Medicinal Chemistry
Book SynopsisWhat defines a quality lead, where these quality leads come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry. This volume addresses these questions and discusses diabetes, obesity and tuberculosis. It presents research in the field of drug discovery.Table of ContentsPreface List of Contributors Hit and Lead Identification: Efficient practices for drug discovery DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor Tuberculosis chemotherapy: recent developments and future perspectives Subject Index Author Index (Volumes 1-45) Subject Index (Volumes 1-45)
£151.05
John Wiley & Sons Inc Comprehensive Quality by Design for
Book SynopsisThis book is a structured approach to designing a product and its associated manufacturing process. It shows pharmaceutical engineers and scientists involved in product and process development how to utilize QbD practices and applications effectively while complying with government regulations.Table of ContentsList of Contributors xiiiPreface xix1 Introduction 1Christine Seymour and Gintaras V. Reklaitis1.1 Quality by Design Overview 11.2 Pharmaceutical Industry 21.3 Quality by Design Details 31.4 Chapter Summaries 4References 72 An Overview of the Role of Mathematical Models in Implementation of Quality by Design Paradigm for Drug Development and Manufacture 9Sharmista Chatterjee, Christine M. V. Moore, and Moheb M. Nasr2.1 Introduction 92.2 Overview of Models 92.3 Role of Models in QbD 122.4 General Scientific Considerations for Model Development 202.5 Scientific Considerations for Maintenance of Models 222.6 Conclusion 23References 233 Role of Automatic Process Control in Quality by Design 25Mo Jiang, Nicholas C. S. Kee, Xing Yi Woo, Li May Goh, Joshua D. Tice, Lifang Zhou, Reginald B. H. Tan, Charles F. Zukoski, Mitsuko Fujiwara, Zoltan K. Nagy, Paul J. A. Kenis, and Richard D. Braatz3.1 Introduction 253.2 Design of Robust Control Strategies 313.3 Some Example Applications of Automatic Feedback Control 353.4 The Role of Kinetics Modeling 403.5 Ideas for a Deeper QbD Approach 423.6 Summary 44Acknowledgments 46References 474 Predictive Distributions for Constructing the ICH Q8 Design Space 55John J. Peterson, Mohammad Yahyah, Kevin Lief, and Neil Hodnett4.1 Introduction 554.2 Overlapping Means Approach 564.3 Predictive Distribution Approach 594.4 Examples 614.5 Summary and Discussion 68Acknowledgments 69References 695 Design of Novel Integrated Pharmaceutical Processes: A Model]Based Approach 71Alicia Román]Martínez, John M. Woodley, and Rafiqul Gani5.1 Introduction 715.2 Problem Description 735.3 Methodology 765.4 Application: Case Study 805.5 Conclusions 91References 916 Methods and Tools for Design Space Identification in Pharmaceutical Development 95Fani Boukouvala, Fernando J. Muzzio, and Marianthi G. Ierapetritou6.1 Introduction 956.2 Design Space: A Multidisciplinary Concept 986.3 Integration of Design Space and Control Strategy 1026.4 Case Studies 1026.5 Conclusions 119Acknowledgment 120References 1207 Using Quality by Design Principles as a Guide for Designing a Process Control Strategy 125Christopher L. Burcham, Mark LaPack, Joseph R. Martinelli, and Neil McCracken7.1 Introduction 1257.2 Chemical Sequence, Impurity Formation, and Control Strategy 1307.3 Mass Transfer and Reaction Kinetics 1407.4 Optimal Processing Conditions 1657.5 Predicted Product Quality under Varied Processing Conditions 1747.6 Conclusions 186Acknowledgments 187Notation 187Acronyms 187Symbols 187Notes 189References 1898 A Strategy for Tablet Active Film Coating Formulation Development Using a Content Uniformity Model and Quality by Design Principles 193Wei Chen, Jennifer Wang, Divyakant Desai, Shih]Ying Chang, San Kiang, and Olav Lyngberg8.1 Introduction 1938.2 Content Uniformity Model Development 1978.3 RSD Model Validation and Sensitivity Analysis for Model Parameters 2128.4 Model]Based Design Space Establishment for Tablet Active Film Coating 2198.5 Summary 229Notations 230References 2309 Quality by Design: Process Trajectory Development for a Dynamic Pharmaceutical Coprecipitation Process Based on an Integrated Real]Time Process Monitoring Strategy 235Huiquan Wu and Mansoor A. Khan9.1 Introduction 2359.2 Experimental 2379.3 Data Analysis Methods 2399.4 Results and Discussion 2409.5 Challenges and Opportunities for PCA]Based Data Analysis and Modeling in Pharmaceutical PAT and QbD Development 2509.6 Conclusions 252Acknowledgments 252References 25310 Application of Advanced Simulation Tools for Establishing Process Design Spaces Within the Quality by Design Framework 257Siegfried Adam, Daniele Suzzi, Gregor Toschkoff, and Johannes G. Khinast10.1 Introduction 25710.2 Computer Simulation]Based Process Characterization of a Pharmaceutical Blending Process 26110.3 Characterization of a Tablet Coating Process via CFD Simulations 27610.4 Overall Conclusions 294References 29511 Design Space Definition: A Case Study—Small Molecule Lyophilized Parenteral 301Linas Mockus, David LeBlond, Gintaras V. Reklaitis, Prabir K. Basu, Tim Paul, Nathan Pease, Steven L. Nail, and Mansoor A. Khan11.1 Introduction 30111.2 Case Study: Bayesian Treatment of Design Space for a Lyophilized Small Molecule Parenteral 30211.3 Results 30711.4 Conclusions 311Appendix 11.A Implementation Using WinBUGS and R 311Shelf Life 315Notation 316Acknowledgments 317References 31712 Enhanced Process Design and Control of a Multiple]Input Multiple]Output Granulation Process 319Rohit Ramachandran12.1 Introduction and Objectives 31912.2 Population Balance Model 32012.3 Simulation and Controllability Studies 32312.4 Identification of Existing “Optimal” Control]Loop Pairings 32712.5 Novel Process Design 33012.6 Conclusions 335References 33613 A Perspective on the Implementation of QbD on Manufacturing through Control System: The Fluidized Bed Dryer Control with MPC and NIR Spectroscopy Case 339Leonel Quiñones, Luis Obregón, and Carlos Velázquez13.1 Introduction 33913.2 Theory 34013.3 Materials and Methods 34413.4 Results and Discussion 34813.5 Continuous Fluidized Bed Drying 35513.6 Control Limitations 35613.7 Conclusions 357Acknowledgment 357References 35714 Knowledge Management in Support of QbD 361G. Joglekar, Gintaras V. Reklaitis, A. Giridhar, and Linas Mockus14.1 Introduction 36114.2 Knowledge Hierarchy 36314.3 Review of Existing Software 36414.4 Workflow]Based Framework 36514.5 Drug Substance Case Study 36814.6 Design Space 37414.7 Technical Challenges 38214.8 Conclusions 384References 385Index 387
£134.06
Elsevier Health Sciences Aultons Pharmaceutics
Book SynopsisTable of ContentsPreface ....................................................................... vii Contributors ............................................................. ix Acknowledgements .................................................. xiii What is 'pharmaceutics'?......................................... xv Kevin M.G. Taylor and Michael E. Aulton 1. Design of dosage forms.................................. 1 Peter York 2. Dissolution and solubility ............................. 13 Michael E. Aulton 3. Properties of solutions ................................... 30 Michael E. Aulton 4. Surfaces and interfaces ................................... 39 Graham Buckton 5. Disperse systems.............................................. 50 David Attwood 6. Rheology........................................................... 81 Christopher Marriott 7. Kinetics ............................................................. 101 Gareth R. Williams and John P. Malkinson 8. Solid-state properties .................................... 114 Graham Buckton 9. Particle size analysis ..................................... 126 Kevin M.G. Taylor 10. Particle size reduction and size separation....................................................... 143 Michael E. Aulton 11. Mixing............................................................. 156 Andrew M. Twitchell 12. Powder flow................................................... 172 Michael E. Aulton 13. Fundamentals of microbiology................... 184 Lara-Marie Barnes and Geoffrey W. Hanlon 14. Pharmaceutical applications of microbiological techniques.......................... 208 Lara-Marie Barnes and Norman A. Hodges 15. Action of physical and chemical agents on microorganisms....................................... 229 Lara-Marie Barnes, Geoffrey W. Hanlon and Norman A. Hodges 16. Principles of sterilization ............................. 247 Susannah E. Walsh, Katie Laird and Jean-Yves Maillard 17. Sterilization in practice ................................ 257 Jean-Yves Maillard, Katie Laird and Susannah E. Walsh 18. Introduction to biopharmaceutics.............. 275 Marianne Ashford and Kevin M.G. Taylor 19. Gastrointestinal tract e physiology and drug absorption............................................. 279 Marianne Ashford and Kevin M.G. Taylor 20. Bioavailability e physicochemical, dosage form and formulation factors ........ 297 Marianne Ashford, Kevin M.G. Taylor and Hala M. Fadda 21. Assessment of biopharmaceutical properties ....................................................... 320 Marianne Ashford and Kevin M.G. Taylor 22. Dosage regimens ........................................... 343 Soraya Dhillon and Nkiruka Umaru 23. Pharmaceutical preformulation .................. 360 Simon Gaisford 24. Solutions ........................................................ 386 Sudaxshina Murdan 25. Clarification ................................................... 397 Andrew M. Twitchell 26. Suspensions ................................................... 407 Susan A. Barker 27. Emulsions and creams ................................. 424 Gillian M. Eccleston 28. Ointments, pastes, gels, cutaneous patches and topical sprays........................... 453 Majella E. Lane 29. Powders, granules and granulation ............ 463 Michael E. Aulton 30. Drying............................................................. 483 Michael E. Aulton and Satyanarayana Somavarapu 31. Tablets and compaction............................... 501 Göran Alderborn and Göran Frenning 32. Modified-release oral drug delivery ............ 542 Emma L. McConnell, Christine M. Madla and Abdul W. Basit 33. Coating of tablets and multiparticulates ... 558 Stuart C. Porter 34. Continuous manufacturing of tablets ........ 574 Aktham Aburub and Hala M. Fadda 35. Hard capsules ................................................ 586 Brian E. Jones 36. Soft capsules .................................................. 599 Stephen Tindal 37. Dissolution testing of solid dosage forms............................................................... 612 Ana Cristina Freire, Francesca K.H. Gavins and Abdul W. Basit 38. Parenteral drug delivery ............................... 626 Robert Lowe 39. Pulmonary drug delivery ............................. 641 Kevin M.G. Taylor 40. Nasal drug delivery....................................... 658 Gary P. Martin and Alison B. Lansley 41. Ocular drug delivery..................................... 677 Hala Fadda, Ashkan Khalili, Peng Tee Khaw and Steve Brocchini 42. Otic drug delivery ......................................... 701 Xu Liu, Hugh Smyth and Feng Zhang 43. Topical and transdermal drug delivery ...... 713 Adrian C. Williams 44. Rectal and vaginal drug delivery................. 735 Kalliopi Dodou 45. Preparation and delivery of biopharmaceuticals....................................... 752 Ijeoma F. Uchegbu and Andreas G. Schätzlein 46. Pharmaceutical nanotechnology and nanomedicines .............................................. 768 Yvonne Perrie 47. Radiopharmaceuticals................................... 789 Neil Hartman and Margaret Cooper 48. The formulation and manufacture of plant medicines............................................. 805 G. Brian Lockwood 49. Design and administration of medicines for paediatric and geriatric patients............ 818 Catherine Tuleu, Mine Orlu and David Wright 50. Packaging ....................................................... 833 Sudaxshina Murdan 51. Chemical stability in dosage forms............ 848 Andrew R. Barnes and Mark Santillo 52. Microbial contamination, spoilage and preservation of medicines............................ 860 Norman A. Hodges and Lara-Marie Barnes 53. Product stability and stability testing......... 871 Paul Marshall 54. Pharmaceutical quality: the application of pharmaceutics in medicines regulation ....................................................... 894 Kevin M.G. Taylor, Majella E. Lane and Khalid A. Sheikh Self-assessment questions Sudaxshina Murdan Please check your eBook at https://studentconsult. inkling.com/ for self-assessment questions. See inside cover for registration details. Index.......................................................................... 915
£50.39
CRC Press Physiological Pharmaceutics
Book SynopsisIn recent years, the emphasis in drug development has been the design of new delivery systems rather than new drugs. It is the aim of innovative pharmaceutical scientists to design the new dosage forms to overcome the body's barrier mechanisms which have specifically evolved to exclude foreign material.This book provides an integrated approach to the study of drug formulation in the body with the emphasis on the formulation variables rather than the drugs. The link between physiology and pharmaceutics is presented to give an essential background of biological principles for the pharmacy student, pharmaceutical formulator and healthcare professional. Complex mathematical aspects of physical chemistry have been avoided to facilitate understanding, enabling the reader to concentrate on how the biological environment affects the performance of the drugs and dosage forms. As the majority of drugs are administered via the oral route a large proportion of the book is devoted to theTrade Review'Provides essential information...There is no equivalent source work.' '...a worthwhile and valuable contribution to this area.'Table of Contents1. Cell Membranes, Epithelial Barriers and Drug Absorption 2. Parenteral Drug Delivery 3. Drug Delivery to the Oral Cavity or Mouth 4. Oesophageal Transit 5. The Stomach 6. Drug Absorption from the Small Intestine 7. Drug Delivery to the Large Intestine and Rectum 8. Transdermal Drug Delivery 9. Nasal Drug Delivery 10. Pulmonary Drug Delivery 11. Ocular Drug Delivery 12. Vaginal and Intrauterine Drug Delivery.
£65.54
Taylor & Francis Ltd Ibuprofen A Critical Bibliographic Review Taylor
Book SynopsisIbuprofen is widely used throughout the world for a variety of conditions. This reference work provides a comprehensive and critical review of the basic science and clinical aspects of the drug. The book begins with the history and development of the drug and its current patterns of use world- wide before moving on to examine its basic pharmaceutical attributes and medicinal chemistry. The properties of various formulations are described (oral prescription and OTC, topical and others) are described. The pharmacokinetics of ibuprofen in animals and humans is discussed - highlighting the factors affecting absorption, distribution, metabolism and elimination. The clinical pharmacology and toxicology and the drug's mechanisms of action in different disease states and conditions are covered. The therapeutic uses in various acute and inflammatory conditions is detailed. Also considered are the safety versus efficacy issues and the pharmacoepidemiological data.Table of Contents1. History and Development of Ibuprofen K.D. Rainsford 2. The Medicinal Chemistry of Ibuprofen K.J. Nichol 3. The Pharmaceutics of Ibuprofen F. Higton 4. The Pharmacokinetcs of Ibuprofen in Humans and Animals D.R. Brocks and F. Jamaili 5. Pharmacology and Toxicology of Ibuprofen K.D. Rainsford 6. Therapeutics of Ibuprofen in Rheumatic and Other Chronic and Painful Diseases W.F. Kean, W.W. Buchanan and K.D. Rainsford 7. Safety and Efficacy of Non-Prescription (OTC) Ibuprofen K.D. Rainsford 8. Use of Ibuprofen in Dentistry R.A. Dionne and S.A. Cooper 9. Gastrointestinal Adverse Drug Reactions Attributed to Ibuprofen D.A. Henry, A. Drew and S. Beuzeville 10. Renal Effects of Ibuprofen M.D. Murray and D.C. Brater 11. Adverse Drug Reactions Attributed to Ibuprofen: Effects Other Than Gastrointestinal L.J. Miwa and J.K. Jones 12. Human Toxicity of Ibuprofen G.N. Volans and R. Fitzpatrick Nichol, Boots Pharmaceuticals, UK, F. Higton, Boots Healthcare International, D.R. Brock, Western University of Health Sciences, USA, F. Jamaili, University of Alberta, USA, W.F. Kean, McMaster University, Canada, W.W. Buchanan, Sir William Osler Health Institute, Canada, R.A. Dionne, National Istitute of Health, USA, S.A. Cooper, Whitehall-Robins Health Care, USA, D.A. Henry, Newcastle Mater Hospital, Australia, A. Drew, Newcastle Mater Hospital, Australia, S. Beuzeville, Newcastle Mater Hospital, Australia, M.D. Murray, Regenstrief Health Centre, USA, D.C. Brater, Indiana university School of Medicine, USA, L.J. Miwa, The Degge Group, USA, J.K. Jones, The Degge Group, USA, G.N. Volans, Guys and St. Thomas' Hospital Trust, UK, R. Fitzpatrick, Guys and St. Thomas' Hospital Trust, UK.
£266.00
Taylor & Francis Ltd Interindividual Variability in Human Drug
Book SynopsisThe book provides an exhaustive, authoritative and updated review on the interindividual variability in drug metabolism in humans. Four chapters address the general background: genetic factors causing variability, interethnic variability, environmental factors and developing and ageing as sources of variability. Six chapters address variability of drug metabolism in vivo: variability of psychotropic drugs, antiepileptic drugs, the dopamine precursor levodopa, cardiovascular active drugs and anti HIV drugs. Seven chapters address the interindividual variability of the main drug metabolizing enzymes: CYP-450s, acetyltransferases, glucuronosyl transferase, methyl transferases, sulfotransferases and glutathione transferases in human liver and extrahepatic tissues. A separate chapter discusses the prediction of drug interaction.Comprehensive in coverage, and with contributions from the leading international experts, this book is essential reading for researchers from both academiTable of ContentsGenetic Factors That Cause Variability in Human Drug Metabolism. Interethnic Differences in Drug Disposition and Effects. Developing and Ageing as Sources of Variability in Drug Metabolism. Genetic and Environmental Factors Causing Variability in Psychotropic Drug Response. Interindividual Variability in the Metabolism of Cardiovascular Drugs. Interindividual Variability in the Metabolism of Antiepileptic Drugs and its Clinical Implications. Variability in the Metabolism of Levodopa and its Clinical Implications. Interindividual Variability in the Disposition of Anti-HIV Drugs. Predictive Modeling of in vivo Drug Interaction From in vitro Data: From Theory to a Computer-based Workbench and Experimental Validation. Interindividual Variation of P450 Enzymes in vitro and it's Causes. Interindividual Variability of Arylamine N-acetyltransferases. Interindividual Variation of UDP-glucuronosyl Transferases and Drug Glucuronidation. Interindividual Variability of Methyltransferases. Interindividual Variability of Sulpho Transferases. Interindividual Variability of Glutathione Transferase Expression
£237.50
Taylor & Francis Ltd Aspirin and Related Drugs
Book SynopsisReviewing over a century of aspirin research and use, Aspirin and Related Drugs provides a comprehensive source of information on the history, chemistry, absorption in the body, therapeutic effects, toxicology, elimination, and future uses of aspirin.Highlighting the historical evolution of the salicylates and the commercial development of aspirin, the book reviews the pharmacokinetics of the salicylates, ibuprofen, and paracetamol as a basis for understanding the biodisposition of these analgesic drugs. Leading specialists discuss the therapeutic role of aspirin in the prevention and treatment of thrombo-embolic diseases, its place along with non-acetylated salicylates in the treatment of rheumatic diseases and plain, and the potential applications for aspirin and related drugs as prophylactics for colon cancer, Alzheimer's disease, and vascular dementia. They also present comparisons with other drugs used to treat pain and inflammation.With extensive data and literTable of ContentsHistory and Development of the Salicylates. The Industrial History of Analgesics: The Evolution of Analgesics and Antipyretics. Occurrence, Properties and Synthetic Developments of the Salicylates. Pharmacokinetics and Metabolism of the Salicylates. Metabolism and Pharmacokinetics of Ibuprofen. Pharmacokinetics and Metabolism of Paracetamol (Acetaminophen). Pharmacology and Biochemistry of Salicylates and Related Drugs. Side-effects and Toxicology of the Salicylates. Reye's Syndrome and Aspirin. Salicylates in the Treatment of Acute Pain. Acetysalicylic Acid for the Prevention and Treatment of Thromboembolic Diseases. Use of Salicylates in Rheumatic and Related Conditions. Aspirin and NSAIDs in the Prevention of Cancer, Alzheimer's Disease and other Novel Therapeutic Actions.
£209.00
IOP Publishing Biopharmaceutical Manufacturing Volume 2
Book Synopsis
£23.75
CRC Press Natural Substances for Cancer Prevention
Book SynopsisNatural Substances for Cancer Prevention explores in detail how numerous investigations in chemical biology and molecular biology have established strong scientific evidence demonstrating how the properties of naturally occurring bioactive chemicals hamper all stages of cancers (from initiation to metastasis).Accordingly, important goals for cancer prevention are the modification of our dietary habits and an increase in the intake of more anticancer-related natural substances. More significantly, the bioactive chemicals presented in the functional foods should be readily available, inexpensive, non-toxic, and nutritional.Table of ContentsPrefaceAuthorIntroductionChapter 1 Cancer-Preventive Substances in Green Vegetables1. Amaranth2. Asparagus3. Brassicaceae Vegetables4. Celery5. Chive6. Chinese Garlic and Scallion7. Leek8. SpinachChapter 2 Cancer-Preventive Substances in Fruit and Flower Vegetables9. Artichoke10. Bitter Gourd/Bitter Melon11. Cochinchin Gourd/Gac Fruit12. Eggplant13. Myoga Ginger14. Okra15. Pumpkin16. TomatoChapter 3 Cancer-Preventive Substances in Root Vegetables17. Carrot18. Garlic19. Onion20. Konjac/Moyu21. Potato22. Red Beet or Chard23. Sweet PotatoChapter 4 Cancer-Preventive Substances in Grains and Beans24. Adlay, Coixseed, or Job’s Tears25. Barley26. Buckwheat27. Common Beans28. Corn29. Foxtail Millet30. Mung Bean31. Oat32. SoybeanChapter 5 Cancer-Preventive Substances in Fruits33. Avocado34. Cherry35. Chestnut Rose36. Citrus Fruits37. Cranberry38. Fig Fruit39. Grape40. Guava41. Hawthorn Berry42. Jujube43. Kiwi Fruit44. Mango45. Papaya46. Persimmon47. Pomegranate48. Ume, Chinese Plum, or Japanese ApricotChapter 6 Cancer-Preventive Substances in Flavorings49. Chili Pepper50. Chinese Pepper51. Lemongrass52. Fennel53. Ginger54. Rosemary55. Star Anise56. ThymeChapter 7 Cancer-Preventive Substances in Beverages57. Coffee58. TeaChapter 8 Cancer-Preventive Substances in Mushrooms59. Bamboo Fungus or Veiled Lady Mushroom60. Golden Oyster Mushroom61. Jew’s Ear, Jelly Ear, or Judas’s Ear62. Lion’s Mane Mushroom63. Maitake or Signorina Mushroom and Chestnut Mushroom64. Mongolia Tricholoma65. Oyster Mushroom66. Pine Mushroom67. Princess Matsutake or Brazilian Mushroom68. Ringless Honey Mushroom69. Shiitake or Sawtooth Oak Mushroom70. Snow Fungus71. Split Gill Mushroom72. Straw Mushroom73. Winter Mushroom or EnokitakeChapter 9 Cancer-Preventive Substances in Seaweeds74. Alga Gloiopeltidis75. Chipolata Weed76. Dried Moss of Enteromorphites or Hutai77. Hijiki78. Kelp79. Kurome80. Laver or Nori81. Sea Mustard82. UmitoranooChapter 10 Cancer-Preventive Substances in Microalgae83. Chlorella84. Spherical Nostoc85. SpirulinaChapter 11 Cancer-Preventive Substances in Animal-Based Foods86. Fresh-Water Mussels87. Marine Mussels88. Hard Clam89. Other Clams90. Sepia Ink91. Calamari Ink92. Sea Cucumber93. Lollyfish Sea CucumberIndex of Latin Names for Functional ComestiblesIndex of English Names for Functional ComestiblesIndex of Acronyms
£237.50
CRC Press Handbook of Analytical Validation
Book SynopsisWritten for practitioners in both the drug and biotechnology industries, the Handbook of Analytical Validation carefully compiles current regulatory requirements on the validation of new or modified analytical methods. Shedding light on method validation from a practical standpoint, the handbook: Contains practical, up-to-date guidelines for analytical method validation Summarizes the latest regulatory requirements for all aspects of method validation, even those coming from the USP, but undergoing modifications Covers development, optimization, validation, and transfer of many different types of methods used in the regulatory environment Simplifying the overall process of method development, optimization and validation, the guidelines in the Handbook apply to both small molecules in the conventional pharmaceutical industry, as well as well as the biotech industry.Trade Review"The authors are to be congratulated on producing a concise, readable and informative book. It is a really useful reference asset covering current regulatory requirements on the validation of new or modified analytical methods from a practical viewpoint. I have seen books of almost twice the size containing half the information. This book should be an integral part of all drug and biotechnology laboratories for both training staff and for comprehensive advice on how to deal with a very wide range of specific issues relating to AMV."—www.chemistryworld.org 1 November 2012 1 Chemistry World 163Table of ContentsIntroduction to Analytical Method Validation. Analytical Instrument Qualification. HPLC Method Development and Optimization with Validation in Mind. Method Validation Basics. Robustness and System Suitability. Setting Specifications and Investigating Out-of-Specification Results. Validation by Type of Method. Analytical Method Transfer. Implementing New Technology in a Regulated Environment. Glossary of Terms Related to Chromatographic Method Validation.
£166.25
Taylor & Francis Inc Industrialization of Drug Discovery
Book SynopsisThe drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and industrialization with the challenges of using the tools available to their best advantage. The book explores early successes, examines the current state of the art, and provides a strategic analysis of the issues currently facing drug discovery.Introducing the historical background and current status of the industry, the book delineates the basic tenets underlying modern drug discovery, how they have evolved, and their use in various approaches and strategies. It examines, in detail, the regulations, requirements, guidelines, and draft documents that guide so many FDA actions. The editor devotes the remainder of the discussion to industrialization, compound and knowledge management functions, the drug screening process, collaboration, and finally, ethical issues. Drawing on real-life, from-the-trenches examples, the book elucidates a new approach to drug discovery and development. This modern-day, back-to-basics approach includes three steps: understand the science, unravel the story, and then intelligently apply the technology, bringing to bear the entire armamentarium of industrialization techniques, not just automation, to the discovery process. Using these steps, you can meet the goals of more specific targets, more selective compounds, and decreased cycle times. In effect, you can look for a bigger needle in a smaller haystack. Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.Trade Review“The book comprises of 10 well-defined chapters. Detailed discussion on historical background to drug discovery in modern age consists of basic concepts, how they have evolved and various approaches and strategies in modern drug discovery. … The book provides a very good review on all aspects of industrialization of drug discovery. … the book is of particular interest since it gives a systematic and in depth account of related topics to transform research into industrialization. This is a very good book of relevance to anyone interested in drug discovery and more, so for all personnel working in drug discovery.” —K. S. Laddha, Reader in Pharmacognosy, University Institute of Chemical Technology, Mumbai, in Chemical Industry Digest, February 2007"Chapter 4, the best part of the book, is an extensive and excellent discussion of aspects of compound- library management. The authors of this chapter have considered all basic aspects of this important component of drug discovery . . . well written with extensive references." – Robert Goodnow, Hoffmann-LaRoche, in ChemMedChem, 2006, No. 3Table of ContentsDrug Discovery in the Modern Age: How We Got Here and Where Do We Go?. The Regulatory Age. Industrialization Not Automation. Compound Management. High Throughput Screening. Parallel Lead Optimization. Knowledge Management. ROI – How to Measure It? How to Get It?. Collaboration in a Virtual and Global Environment. From Genome to Drug: Ethical Issues.
£190.00
Taylor & Francis Inc Ironies In Organizational Development Revised And
Book SynopsisA True Insider's Guide to the Field Then and Now Until now, there has not been a book that effectively addresses the historical basis of protein discovery. Featuring contributions from a distinguished international panel of experts, Protein Discovery Technologies elucidates the principles, techniques, strategies, and broad range of applications of protein discovery by documenting the often untold stories and personal accounts of the contributors' past scientific achievements.Incorporates Short, Personal Discovery Vignettes Rather than an exhaustive field analysis, this globally pertinent resource presents in-depth discussions of various methods for protein discovery, including bioinformatics, interaction cloning, protein purification, phage display, non-primate models, and chemical targeting. It also explores biological themes through the examination Table of ContentsDiscovery of Vascular Permeability Factor (VPF, VEGF, VPF/VEGF, VEGF-A165). Tumor Necrosis Factor and Its Family Members. Blood–Brain Barrier Models for Investigating CNS Pathologies. Identification of Activation of Latent TGFß as Principal In Vivo Function of Integrin avß6. Purification of Basic Fibroblast Growth Factor by Heparin Affinity. How It Came to Pass that Interferon Was Used as an Angiogenesis Inhibitor. Use of Phage Display to Discover Inhibitors of Cell Migration. Combinatorial Mapping of Vascular Zip Codes by In Vivo Phage Display. Chasing Elusive Cellular Prion Protein Receptor. Discovery of Molecular Chaperone GRP78 and GRP94 Inducible by Endoplasmic Reticulum Stress. Origin of Sphingomyelin Pathway. Endotoxin-Induced Myocarditis: A New Pathophysiological Entity in Systemic Inflammatory Response Syndrome. Discovery of DOCK180 Superfamily of Exchange Factors. Discovery of Extracellular Matrix Degradome as Novel Endogenous Regulators of Angiogenesis and Tumor Growth. RING Finger Proteins as E3 Ubiquitin Ligases. Discovery of Chemical Nature of Cross-Links in Collagen: A Personal Retrospective. Discovery of SPARC as Prototype for Matricellular Proteins.
£162.00
Taylor & Francis Inc Virtual Screening in Drug Discovery 1 Drug
Book SynopsisVirtual screening can reduce costs and increase hit rates for lead discovery by eliminating the need for robotics, reagent acquisition or production, and compound storage facilities. The increased robustness of computational algorithms and scoring functions, the availability of affordable computational power, and the potential for timely structural determination of target molecules, have provided new opportunities for virtual screening, and made it more practical. Why then, isn't everyone using virtual screening? Examining the scope and limitations of this method, Virtual Screening in Drug Discovery explores the algorithms involved and how to actually use them. Part I offers perspectives on both ligand-based and docking-based virtual screens. The authors of these chapters frame many of the challenges currently facing the field. Part II considers the choice of compounds that are best suited as drug leads. Part III discusses ligand-based approaches, incluTable of ContentsPerspectives on Virtual Screening. Compound and Hit Suitability for Virtual Screening. Ligand-Based Virtual Screening Approaches. Important Considerations Impacting Molecular Docking. Docking Strategies and Algorithms.
£199.50
CRC Press Encyclopedia of Medical Genomics and Proteomics
Book SynopsisUpdating researchers on phenomenal progress in the field of molecular medicine the Encyclopedia of Medical Genomics and Proteomics offers trail-blazing studies and authoritative contributions from more than 400 specialists. An important and timely contribution to the biomedical community, the encyclopedia compiles recommendations and research and features coverage of key methods and technologies related to a range of areas. Topics include:Molecular diagnosticsGenomics, microbiology, genetics, and pharmacogeneticsManagement of infectious, neoplastic, and genetic diseasesTreatment of chronic, hereditary, and congenital disordersMedical applications of nucleic acid and protein technologyCell typingDisease susceptibility Predictive genetic and pharmacogenetic testing and tissue typing for transplantationDNA sequencing, point-of-care testing, and quality managementOncology and cancer screeningPathology and forensic issuesDiagnostic microbiology and molecular pathologyEthical issues related to genetics Also Available OnlineThis Taylor & Francis encyclopedia is also available through online subscription, offering a variety of extra benefits for researchers, students, and librarians, including:Citation tracking and alertsActive reference linkingSaved searches and marked listsHTML and PDF format optionsContact Taylor and Francis for more information or to inquire about subscription options and print/online combination packages.US: (Tel) 1.888.318.2367; (E-mail) e-reference@taylorandfrancis.comInternational: (Tel) +44 (0) 20 7017 6062; (E-mail) online.sales@tandf.co.uk
£593.75
Taylor & Francis Inc Thermal Analysis of Pharmaceuticals
Book SynopsisAs a result of the Process Analytical Technologies (PAT) initiative launched by the U.S. Food and Drug Administration (FDA), analytical development is receiving more attention within the pharmaceutical industry. Illustrating the importance of analytical methodologies, Thermal Analysis of Pharmaceuticals presents reliable and versatile characterization tools for the successful development of pharmaceutical products. It draws attention to the most widely applicable methods and demonstrates how to interpret the associated data.The book opens with the first three chapters devoted to differential scanning calorimetry (DSC), the most commonly used thermal method. These chapters cover the principles, optimal use, and pharmaceutical applications of the method. Subsequent chapters explore modulated temperature DSC, thermogravimetric analysis, thermal microscopy, microcalorimetry, high sensitivity DSC, dynamic mechanical analysis, and thermally stimulated current, all of which hTrade Review“… presents reliable and versatile characterization tools for the successful development of pharmaceutical products. It draws attention to the most widely applicable methods and demonstrates how to interpret the associated data. … achieves and ideal balance in the depth, relevance, and accessibility of topic presented. The book provides an excellent overview of this key area in pharmaceutical development.” — In Anticancer Research, Vol. 27, No. 3B, May/June 2007"The editors did a really good job in creating a fine balance between topics of commonly used, well-established methods, and of techniques that are the focus of recent research efforts . . . Due to the high scientific value, timely industrial relevance, and didactic approach, this book is an invaluable information resource for readers both in academia and industry, be they beginners or experts. I warmly recommend this book to everybody involved in solid-state analysis of pharmaceuticals, because it is the must have that I have long been waiting for." – Dr. Ádám Demeter, Gedeon Richter Plc, in ChemMedChem, 2008, No. 3Table of ContentsPrinciples of Differential Scanning Calorimetry. Optimizing DSC Experiments. Pharmaceutical Applications of DSC. Modulated Temperature Differential Scanning Calorimetry. Thermogravimetric Analysis: Basic Principles. Thermogravimetric Analysis: Pharmaceutical Applications. Thermal Microscopy. Principles and Pharmaceutical Applications of Isothermal Microcalorimetry. High Sensitivity Differential Scanning Calorimetry. Thermorheological (Dynamic Oscillatory) Characterisation of Pharmaceutical and Biomedical Polymers. The Use of Thermally Stimulated Current Spectroscopy within the Pharmaceutical Sciences.
£199.50
Taylor & Francis Inc Interpharm Master Keyword Guide 21 CFR
Book SynopsisThis guide contains over 20,000 entries completely cross-indexed and quoted in context to provide readers with instant access to every noun, phrase, and concept used by the Drug Enforcement Administration and U.S. Food and Drug Administration.Table of ContentsContents are listed alphabetically.
£171.00
Taylor & Francis Inc Sterile Product Facility Design and Project
Book SynopsisKnowing how to deal with the regulatory issues, understanding the impacts of cleanliness, and recognizing the affect that poor facility layout will have on GMP spaces are only some of the issues an experienced Project Manager must focus on. Completely revised and updated, Sterile Product Facility Design and Project Management, Second Edition provides comprehensive guidance on how to develop and execute biotech and other sterile drug facilities based on current industry best practices. Each chapter highlights a specific issue centered on managing biotech facilities projects in a GMP environment. The author uses real-world examples of common industry practice to lead you through the idiosyncrasies of a biotech project in an effort to answer some of the more common, and often perplexing, questions that can stand in the way of success. You get a mini seminar on each topic covered.Breaking the project life-cycle into four phases, the text takes you through each phase from thTable of ContentsIntroduction to Facility Project Management Project Formation Defining the Project Team Facility Programming Project Control Current Good Manufacturing Practice (cGMP): Project Impacts Mechanical Systems GMP Compliance in Architectural Design and Construction Commissioning Quality Management to Meet Regulatory Requirements Establishment Licensing Containment Basics Multi-product Facilities for Biologics Contract Formulation and Philosophy Future Trends
£285.00
Taylor & Francis Inc Fluid Sterilization by Filtration
Book SynopsisCompletely revised and updated, Fluid Sterilization by Filtration, Third Edition discusses the use of gas and fluid filtration systems in sterilization technology. Packed with information useful to both the novice and the expert, it includes line-drawing illustrations, filtration setups, and plots of math functions illustrating fluid flows through filter media built from a random packing of solids. The book provides in-depth discussions of general filtration, specific membranes used in filtration, integrity testing, earlier filtration steps, and cross-flow filtration. It also includes a useful, updated appendix of worldwide contacts and many sources for equipment, supplies, and information.Table of ContentsCompletely revised and updated, Fluid Sterilization by Filtration, Third Edition discusses the use of gas and fluid filtration systems in sterilization technology. Packed with information useful to both the novice and the expert, it includes line-drawing illustrations, filtration setups, and plots of math functions illustrating fluid flows through filter media built from a random packing of solids. The book provides in-depth discussions of general filtration, specific membranes used in filtration, integrity testing, earlier filtration steps, and cross-flow filtration. It also includes a useful, updated appendix of worldwide contacts and many sources for equipment, supplies, and information.
£142.50
Taylor & Francis Inc Radiotracers in Drug Development
Book SynopsisAlthough there are numerous books on drug metabolism, Radiotracers in Drug Development is unique in explaining how radiotracers are used to elucidate a drugâs absorption, distribution, metabolism, and excretion (ADME). Covering traditional and recent technologies and applications, the book takes a strong industrial approach, discussing the basics of scintillation counting and untangling the various data processing methods often specific to individual manufacturers.The chapters include descriptions of the latest micro-plate counters and the growing applications of accelerator mass spectrometry, positron emission tomography, gamma-scintigraphy, and radioluminography. In addition to describing how the analytical technologies work, the contributors explain how the data are interpreted and used in the drug registration process. A unique reference and training aid essential for every drug metabolism department or drug metabolism research team, the book provides insighTable of ContentsRadiotracers and Drug Registration. Radioactivity and Radiotracers. The Study of Drug Metabolism Using Radiotracers. DNA Binding, Isotope Dilution, and Other Uses of Radiotracers. Quantitative Whole-Body Autoradiography (QWBA). Scintillation Counting. Statistics in Liquid Scintillation Counting. Instrumentation for Detection of Radioactivity. Sample Preparation for Liquid Scintillation Counting. Biomedical Accelerator Mass Spectrometry. Positron Emission Tomography. Gamma Scintigraphy and SPECT.
£237.50
Taylor & Francis Inc Pharmaceutical Product Development Vol165 In
Book SynopsisDuring the last two decades, the pharmaceutical industry has been under pressure to reduce development costs and the time needed to bring drugs to market in order to maximize return on investment and bring treatments to patients sooner. To meet these ends, pharmaceutical scientists working in the differing areas of pharmacy, pharmaceutics, and pharmacokinetics are collaborating to address physicochemical and biological issues in the early stages of development to avoid problems in later stages. In Vitro-In Vivo Correlation (IVIVC) is a multidisciplinary tool that has been successfully applied in testing the effectiveness of a drug substance. The only comprehensive guide available on IVIVC, this source illustrates the emerging importance of IVIVC in the drug development process, and covers the most recent advances and regulatory perspectives on the role of IVIVC in the pharmaceutical industry.Table of ContentsIntroduction. Dissolution: Fundamentals of In Vitro Drug Release and Biopharmaceutics Classification System (BCS). Pharmacokinetics: Basics of Drug Absorption from a Biopharmaceutical Perspective. IVIVC Models: Development and Validation. Computational Approaches to Develop IVIVC Models. IVIVC - Pharmaceutical Drug/Product Development. Role of IVIVC in the Early Phases of Drug Discovery and Drug Delivery Technology Development. IVIVC - Setting Dissolution Specifications. IVIVC - Oral Drug Delivery: Immediate Release and Extended Release Dosage Forms. In Vitro-In Vivo Correlation for Modified Release Parenteral Drug Delivery Systems. IVIVC - Transdermal and Other Novel/Special Drug Delivery Systems. Regulatory Perspective. Regulatory Guidance on IVIVC: Across the World
£166.25
Taylor & Francis Inc Bioadhesive Drug Delivery Systems
Book SynopsisThis comprehensively written text covers, in-depth, all aspects of bioadhesive systems. Bioadhesive systems are presently playing a major role in the field because of their ability to maintain a dosage form at a precise body-site for a prolonged period of time over which the active principle is progressively released. Included in this book are descriptions of the different mucosae in healthy and pathological situations, a theoretical approach of polymers-mucin interactions, and a comparative description of the methods used to evaluate bioadhesion. Up-to-date reviews of pharmaceutical applications are also given - subdivided according to the route of administration and type of system. It also contains a chapter devoted to the fundamentals of bioadhesion. This reference is an indispensable guide for researchers in the pharmaceutical field as well as academic researchers.Table of ContentsMucus Physiology and Pathology. Scaling Concepts and Molecular Theories of Adhesion of Synthetic Polymers to Glycoproteinic Networks. Test Methods of Bioadhesion. Bioadhesives/Mucoadhesives in Drug Delivery to the Gastrointestinal Tract. Nanoparticles as a Gastroadhesive Drug Delivery System. Mucoadhesive Buccal Patches for Peptide Delivery. Bioadhesive Dosage Forms for Buccal/Gingival Administration. Semisolid Dosage Forms as Buccal Bioadhesives. Bioadhesive Dosage Forms for Nasal Administration. Ocular Bioadhesive Delivery Systems. Nanoparticles as Bioadhesive Ocular Drug Delivery Systems. Bioadhesive Dosage Forms for Vaginal and Intrauterine Applications.
£475.00
Taylor & Francis Inc Degradation of Bioactive Substances
Book SynopsisIntended primarily for researchers working with bioactive substances such as hormones, neurotransmitters, growth factors, and connective tissue makers, this book discusses the principles of degradation in major groups of bioactive materials with respect to physiology, location, and regulation. Peptidases; receptor-mediated endocytosis; organ extraction and clearance; and the degradation of specific proteins, peptides, amines, steroids, and polysaccharoides are featured. Pathophysiology and its role in diagnostics and disease are considered throughout the book, in addition to updates of recent literature and substantial new information on physiology and pathophysiology of degradation of bioactive material. No special mathematical or kinetic background is necessary to read this book because the mathematic and kinetic concepts are facilitated through the presentation of fundamental and more advanced principles. Furthermore, illustrations and tables are provided to facilitate the understanTable of ContentsINTRODUCTION. KINETICS OF WHOLE-BODY AND ORGAN DEGRADATION. Introduction. Compartmental and Multicompartmental Models. Non-Compartmental Models. Whole-Body Degradation. Organ and Tissue Degradation. Conclusion. KINETICS OF ELIMINATION FROM THE BLOOD: PRINCIPLES AND PROCEDURES. Introduction. Kinetic Models in General. Regimes of Elimination. The Concept of Clearance. Special Clearance Regimes. Experimental Procedures. Methodology. Conclusion. PEPTIDASES INVOLVED IN THE METABOLISM OF BIOACTIVE PEPTIDES. Introduction. Properties of the Peptidases. How Do Peptidases Act in Concert? Organ, Tissue and Cellular Locations of Cell Surface Peptidases. Membrane Peptidases as Cluster Differentiation (CD) Antigens. Membrane Anchorage, Release and Plasma Activity of Peptidases. Physiological Roles of Membrane Peptidases. Conclusion. RECEPTOR-MEDIATED ENDOCYTOSIS AND DEGRADATION OF POLYPEPTIDE HORMONES, GROWTH FACTORS AND NEUROPEPTIDES. Perspectives. Receptors for Polypeptide Hormones, Growth Factors and Neuropeptides. Receptor-Mediated Endocytosis. Endocytosis and Degradation of Hormones, Growth Factors, Neuropeptides and Plasma Protein. DEGRADATION OF CIRCULATING RENIN AND ANGIOTENSIN. Introduction. Physiology of Renin and Angiotensin II. Metabolism of Circulating Renin. Metabolism of Circulating Angiotensin II. The Renin-Angiotensin System in Disease. Conclusion. PROCESSING AND CLEARANCE OF ATRIAL NATRIURETIC FACTORS (ANF). Introduction. Processing of ANF Prohormone. Clearance of Bioactive ANF. Conclusion. DEGRADATION OF GASTRIC PEPTIDES: METABOLISM OF THE GASTRINS. Introduction. Structure and Synthesis of the Gastrins. Degradation of the Gastrins. Conclusion. DEGRADATION OF CIRCULATING INTESTINAL PEPTIDES: METABOLISM OF SUBSTANCE P AND VASOACTIVE INTESTINAL POLYPEPTIDE. Introduction. Degradation of Substance P. Degradation of VIP. Conclusion. DEGRADATION OF GLUCAGONS. Introduction. Structure and Synthesis of Glucagon and Related Peptides. Degradation of Glucagon. Degradation o
£498.75
Taylor & Francis Inc Generic Drug Product Development
Book SynopsisThe assessment of bioequivalence is an important process whereby the bioavailability of a generic drug product is compared with its brand-name counterpart. Generic pharmaceutical products must be approved as therapeutic equivalents to the brand name alternative in order to be interchangeable. The demonstration of bioequivalence is an important component of therapeutic equivalence. Bioequivalence studies are very expensive, time consuming and always have the possibility of failure. The objective of this textbook is to describe some of those specific bioequivalence issues which need to be considered for the design and conduct of bioequivalence studies. By exploring scientific, legal, and international regulatory challenges, Generic Drug Development, discusses the use of alternative approaches to the measurement of plasma drug concentrations for the demonstration of bioequivalence, and covers bioequivalence procedures for drug products that are not easily assessed - based upon the physicaTable of ContentsIntroduction - Bioequivalence Issues. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Pharmaceutical Alternatives: Considerations for Generic Substitution. Pharmacodynamic Measurements for Determination of Bioequivalence. Bioequivalence Using Clinical Endpoint Studies. Evaluation of Bioequivalence of Highly-Variable Drug Products. Statistical Considerations: Alternate Designs And Approaches For Bioequivalence Assessments. Population Pharmacokinetic Approaches for Assessing Bioequivalence. Role of Metabolites in Bioequivalence Assessment. Implications of Chirality for the Assessment of Bioequivalence. Effect of Food on Bioavailability and the Assessment of Bioequivalence. Bioequivalence Assessment of Endogenous Drug Substances : Pharmacokinetics and Statistical Evaluation.
£161.50
CRC Press A Practical Guide to Quality Management in
Book SynopsisSetting up a GXP environment where none existed previously is a very daunting task. Getting staff to write down what they do for every task is a correspondingly difficult and time-consuming exercise. Examining how to maintain quality control in clinical trial research, A Practical Guide to Quality Management in Clinical Trial Research provides a cornerstone of knowledge for establishing a quality system that complies with the relevant regulations. There are many books available that cover how to interpret regulations. Going a step or two further, this book provides practical advice that is useful on a daily basis.The book contains information for various standards including GLPs, GCPs, and GMPs. It gives detailed explanations of how to prepare, update, and maintain SOPs and includes advice on training and development of personnel. Drawing directly on his years of experience, the author delineates a from-the-trenches methodology that creates a value-added quality management system from a business perspective. He provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations. The author's integrated approach and anecdotal style turns technically accurate information into easy reading. The book arms you with tools and concepts that you can use to go beyond regulatory compliance and move into the realm of business quality improvement.Trade Review"…provides the reader with a pragmatic approach to the principles governing accepted methodologies within the working environment and provides some useful examples of these interpretational differences across industry."-Quasar"…provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations."--Anticancer ResearchTable of ContentsIn the Beginning There Was GLP. Before GCP. Training in the Regulated Environment. Computing in the Regulated Environment. QA Activity. Beyond Compliance. Business Improvement. A Summary. Appendix: Information Resources and Acronyms.
£166.25
Pharmaceutical Press Pharmaceutical Isolators
Book SynopsisPharmaceutical Isolators is an indispensable guide to the design, construction, commissioning, maintenance, use and monitoring of pharmaceutical isolators.Trade Review'The text is written in a clear and concise manner and desired information is readily accessible.' Linda Felton, University of Mexico, College of Pharmacy, Mexico, Drug Development and Industrial Pharmacy, 1 March 2005 -- Linda A. Felton * Drug Development and Industrial Pharmacy *Table of Contents1. Isolator Applications: 2. Design: 3. Transfer Devices: 4. Access Devices: 5. Siting of Isolators and Clothing Regimes: 6. Cleaning, Decontamination & Disinfection: 7. Physical Monitoring: 8. Leak Testing: 9. Microbiological Monitoring: 10. Validation: 11. Standards and Guidelines: 12. Definiton of Terms: A1. HSE/MCA Guidance: A2. Training: A3. Stainless Steel for Isolators: A4. HEPA Filtration Mechanisms, MPPS and Typical Particle Sizes: A5. Calculations to Estimate the Size of a Leak That Can Be Detected Using DOP: A6. Activated Carbon Filters:
£25.65
Pharmaceutical Press An Introduction to Clinical Pharmaceutics
Book SynopsisConsiders the importance of pharmaceutics and pharmaceutical dosage form design by considering the clinical use of modern drugs. This book also considers the use and behaviour of dosage forms in different age groups and patient groups along with developments such as personalised therapies and genomics.Table of Contents1. Introduction; 2. Drugs and Excipients; 3. Oral Formulations; 4. Parenteral Formulations; 5. Adverse Reactions; 6. Pharmaceutics and the Neonate; 7. Pharmaceutics of Disease States; 8. Advanced Delivery Systems.
£25.65
Pharmaceutical Press Handbook of Extemporaneous Preparation
Book SynopsisA comprehensive and easy-to-follow guide to good practice in extemporaneous compounding.Trade Review"...this resource offers a real advantage to both the prescriber and the pharmacist in the provision of quality oral liquids...Of particular use and unique to this text is the inclusion of a 'risk assessment' section in each monograph which addresses the clinical and technical risks associated with the extemporaneous preparation of each oral liquid...This book is not only a useful resource, but a valuable addition to the texts available on extemporaneous dispensing for those prescribers wanting quick access to suitable oral liquid alternatives..." Alison Haywood, Senior Lecturer, Griffith University, and Beverley Glass, Professor of Pharmacy, James Cook University Queensland, Australian Prescriber 34(5), October 2011. -- Alison Haywood * Australian Prescriber *Table of ContentsPart A - Standards 1. Glossary 2. Introduction 3. Risk Management 4. Quality Management 5. Personnel & Training 6. Premises & Equipment 7. Documentation 8. Preparation 9. Formulation & Stability 10. Quality Control 11. Complaints, Product Recalls & Adverse Events 12. Procurement & Quality Assessment 13. Audit & Monitoring Part B Extemporaneous Preparation Formulary 14. Introduction 15. Data Collection 16. Risk Assessment 17. Formulary of Extemporaneous Preparation
£43.20
Pharmaceutical Press Pharmaceutical Compounding and Dispensing
Book SynopsisThis is a modern, detailed and practical guide to the theory and practice of extemporaneous compounding and dispensing. Fully revised and updated, this new edition will be an indispensable reference for pharmacy students and practicing pharmacists.Trade Review"The book is well received, since there are few textbooks or reference books available devoted specifically to compounding. The authors should be commended for emphasizing the historical content in tandem with the preparation instruction...the book remains a good resource for anyone interested in compounding" Christine R. Birnie, PhD, American Journal of Pharmaceutical Education 75(1), Feb 2011 -- Christine R. Birnie * American Journal of Pharmaceutical Education *
£38.70
Pharmaceutical Press Essentials of Pharmaceutical Chemistry
Book SynopsisEssentials of Pharmaceutical Chemistry is an introduction to pharmaceutical chemistry for undergraduate pharmacy, chemistry and medicinal chemistry students. It covers all of the core material necessary to provide an understanding of the basic chemistry of drug molecules.Trade Review "...Donald Cairns is a well-known educator, mentor, and researcher...this is an excellent resource for pharmacy students taking pharmaceutical chemistry and for individuals who intend to pursue a career in the pharmaceutical industry...Readers will find this as a useful reference." Rahmat M Talukder, Ph.D.,Doody's Notes, May 2012. -- Rahmat M Talukder * Doody's Notes *"This is a great book detailing the basic chemistry of drugs...Throughout the book there are problems that can be worked, and it includes the answers at the end of the book. It is very easy-to-read and has very good graphics to support the discussions. In addition to being a good text, it is a good refresher for those that would like to review this topic."Compounding Today, 27 Jan 2012. * Compounding Today *Table of Contents1. Chemistry of Acids and Bases; 2. Partition Coefficient and Biopharmacy; 3. Physicochemical Properties of Drugs; 4. Stereochemistry; 5. Drug Metabolism; 6. Volumetric Analysis of Drugs; 7. Analytical Spectroscopy; 8. Chromatographic Methods of Analysis; 9. Stability of Drugs and Medicines; 10. Kinetics of Drug Stability; 11. Licensing of Drugs and the British Pharmacopoeia; 12. Medicinal Chemistry - the Science of Rational Drug Design; 13. Answers to Problems
£38.70
Royal Society of Chemistry StructureBased Drug Discovery
Book SynopsisStructure-based drug discovery is a collection of methods that exploits the ability to determine and analyse the three dimensional structure of biological molecules. These methods have been adopted and enhanced to improve the speed and quality of discovery of new drug candidates. After an introductory overview of the principles and application of structure-based methods in drug discovery, this book then describes the essential features of the various methods. Chapters on X-ray crystallography, NMR spectroscopy, and computational chemistry and molecular modelling describe how these particular techniques have been enhanced to support rational drug discovery, with discussions on developments such as high throughput structure determination, probing protein-ligand interactions by NMR spectroscopy, virtual screening and fragment-based drug discovery. The concluding chapters complement the overview of methods by presenting case histories to demonstrate the major impact that structure-based meTrade ReviewWell written......most illuminating.This is a book that the practising medicinal chemist should have at the bedside. * Chemistry & Industry, 26 March 2007 (Christopher Newton) *....good didactic overview....good artwork reinforcing the text.....warmly recommend this book to those about to embark on a structure-based drug design project. There are very few of us who will invent a drug, but by using the techniques described, you will shorten your own odds considerably. * Chemistry World, January 2007, p59 (Richard Lewis) *Table of ContentsChapter 1: 3D Structure and the Drug Discovery Process; 1: Introduction; 2: The Drug Discovery Process; 3: What is Structure-based Drug Discovery?; 4: The Evolution of the Ideas of Structure-based Drug Discovery; 5: What isn't in this Book; 6: Concluding Remarks; References; Chapter 2: Structure Detemination - Crystallography for Structure-based Drug Design; 1: What is X-ray Crystallography?; 2: What is required to Produce a Crystal Structure?; 3: Crystallisability of Proteins; 4: How Does the X-ray Data Relate to the Electron Density? The Phase Problem; 5: Electron Density Map Interpretation and Atomic Model of the Protein; 6: Useful Crystallographic Therminology when Utilising Crystal Structures; 7: The Structure Determination Process; 8: Recent technological Advances; 9: The Role of Crystal Structures in the Discovery Process; 10: The Optimal SBDD System; 11: The Impact of Structural Genomics; 12: Producing a Biologically Relevant Structure; 13: Phosphorylation; 14: Balancing Solubility with Crystallisability; 15: Engineering Solubility; 16: Specific Crystal Packing Engineering; 17: Engineering Stability; 18: Use of Surrogate Proteins; References; Chapter 3: Molecular Modelling; 1: Introduction; 2: Methods; 3: Applications; 4: Conclusion; References; Chapter 4: Applications of NMR in Structure-based Drug Design; 1: Introduction; 2: Studying Ligand/Receptor Interactions by NMR; 3: NMR in Structure-based Lead Optimization; 4: Other Applications of NMR in SBDD; 5: Conclusion and Outlook; References; Chapter 5: Fragment Screening - An Introduction; 1: Introduction; 2: The Concept of Drug Likeness; 3: The Evolution of Lead-likeness and Fragment Screening; 4: Finding Fragments by Screening; 5: The Design of Fragment Screening Sets; 6: Turning Fragment Hits into Leads; 7:Summary; References; Chapter 6: Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally Available Antithrombotic Candadate LY517717; 1: Introduction; 2: Morphology of the Factor Xa Active Site; 3: Structure-based Library Design; 4: Design Strategy for Factor Xa; 5: Introducing Oral Availability; 6: Non-basic S1 Series; 7: Oral Antithrombotic Activity; 8: Conclusion; References; Chapter 7: Anti-influenza Drugs from Sialidase Inhibitors; 1: Introduction; 2: Influenza Viruses; 3: Early Attempts to Discover Neuraminidase Inhibitors; 4: Neuraminidase Structure; 5: Structure-based Discovery of Inhibitors; 6: Retrospective Analyses of Inhibitor-binding; 7: Laboratory Studies of Inhibitor Resistant Variants; 8: Clinical Studies of Drug Resistance; 9: Drug Profiles; Conclusions; References; Chapter 8: Isoform Specificity: The Design of Estrogen Receptor- Selective Compounds; 1: Introduction; 2: Structure-based Design Methodology; 3: The Design of Aryl Diphenolic Azoles as ER? Selective Agonists; 4: Learning From and Moving Beyond the Genistein Scaffold; 5: Evaluation of ER? Selective Compounds in Biological Assays; Conclusions; Acknowledgements; References
£126.34
